EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population‐based study (the Fex‐Can study)

Anu Haavisto iD, Claudia Lampic iD, Lena Wettergren iD, Päivi M Lähteenmäki iD, Kirsi Jahnukainen iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Anu Haavisto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Cancer Survivors, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vetenskapsrådet, Barncancerfonden, Lastentautien Tutkimussäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Childhood cancer survivors are at risk of various endocrine late effects affecting their quality of life. The aim of this study was to assess the prevalence and predictors of endocrine and reproductive outcomes in young adult survivors. A secondary aim was to assess possible associations between testosterone replacement therapy (TRT) and other endocrine, cardiovascular and psychosocial late effects. This nationwide study comprised 1212 male childhood cancer survivors aged 19–40 years, identified through the National Quality Registry for Childhood Cancer in Sweden. Median age at diagnosis during 1981–2017 was 7 (range 0–17) and at study 29 (19–40) years. The study combined self‐report survey data with cancer treatment data from the national registry. Hormone‐induced puberty was self‐reported by 3.8% of the survivors and ongoing TRT by 6.0%. In separate logistic regression analyses, these treatments were associated with hematopoietic stem cell transplantation and cranial radiotherapy. Hormone‐induced puberty was additionally associated with younger age at diagnosis. Men with TRT had a higher prevalence of other endocrine deficiencies, cholesterol medication, depressive symptoms and fatigue as well as a lower probability of living with a partner, having a biological child or current occupation. In the total male cohort, 28.2% reported having a biological child. Reassuring reproductive outcomes after less intensive therapies and low frequency of TRT were observed in young adult male childhood cancer survivors treated in the most recent treatment era. However, men with TRT suffered from several other endocrine, cardiovascular and psychosocial late effects, indicating a need for long‐term monitoring of this high‐risk group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer SurvivorsNeoplasmsYoung AdultHumansMaleChildInfant, NewbornInfantChild, PreschoolAdolescentQuality of LifeLongitudinal StudiesTestosterone

Stichwörter der Autor:innen

childhood cancer survivorslate effectsregistry studysubfertilitytestosterone replacement therapy

Substanzen

Testosterone

Autor:innen und Institutionen

  • Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Faculty of Education and Welfare Studies, Åbo Akademi University, Turku, Finland.
  • Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
  • Department of Psychology, Umeå University, Umeå, Sweden.
  • Department of Pediatric and Adolescent Medicine, Turku University Hospital, Turku, Finland.

ORCID-Profile: Anu Haavisto, Claudia Lampic, Lena Wettergren, Päivi M Lähteenmäki, Kirsi Jahnukainen

Förderung

  • Vetenskapsrådet
  • Barncancerfonden
  • Lastentautien Tutkimussäätiö
  • Cancerfonden
  • Forskningsrådet om Hälsa, Arbetsliv och Välfärd
  • Birgitta and Carl-Axel Rydbeck's Research Grant for Paediatric Research
  • Syöpäsäätiö

Zitieren

APA

Haavisto, A., Lampic, C., Wettergren, L., Lähteenmäki, P. M., & Jahnukainen, K. (2024). Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population‐based study (the Fex‐Can study). International Journal of Cancer. https://doi.org/10.1002/ijc.34890

Vancouver

Haavisto A, Lampic C, Wettergren L, Lähteenmäki PM, Jahnukainen K. Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population‐based study (the Fex‐Can study). International Journal of Cancer. 2024. doi:10.1002/ijc.34890

BibTeX
@article{Haavisto2024,
  author = {Haavisto, Anu and Lampic, Claudia and Wettergren, Lena and Lähteenmäki, Päivi M and Jahnukainen, Kirsi},
  title = {Reproductive late effects and testosterone replacement therapy in male childhood cancer survivors: A population‐based study (the Fex‐Can study)},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34890}
}
Kostenlos starten →